Last update Nov. 1, 2012

Dihydroergocryptyne Mesilate

Very High Risk

Very unsafe. Contraindicated. Use of an alternative or cessation of breastfeeding. Read the Comment.

Ergot-derivative alkaloid with an inhibiting effect on prolactin and dopamine release, used for treatment of prolactinoma, Parkinson’s Disease, brain vascular insufficiency and senile dementia. It may suppress lactation by inhibiting prolactin release.

Nonessential drug.


We do not have alternatives for Dihydroergocryptyne Mesilate.

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.


Dihydroergocryptyne Mesilate belongs to this group or family:


Main tradenames from several countries containing Dihydroergocryptyne Mesilate in its composition:


Variable Value Unit
Molecular weight 674 daltons


  1. [No authors listed] Do not use drugs to prevent onset of lactation. Relieve the discomfort and wait. Prescrire Int. 2013 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by La Liga de la Leche de Euskadi

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM